Sections

Alphabetical list:

A B C D E F G H I J K L M N O P R S T U V W X Y Q Z 1 2 3 4 5 6 7 8 9

News: November 29, 2009

Rituximab May Offer Hope To Severe Graves' Eye Disease Patients

November 29, 2009

There may be hope for patients with severe Graves' eye disease in the form of treatment with the drug rituximab.

This news comes from U-M Kellogg Eye Center who's oculoplastics specialist Raymond S. Douglas, M.D., Ph.D. reports on the potential of the drug in the online October issue of Ophthalmology.

Graves' eye disease is an autoimmune disease that causes inflammation and fatty deposits in the eye muscles and connective tissue surrounding the eye.

Douglas reports on the progress of six patients (four women, two men) who had not responded to treatment using systemic corticosteroids. The patients were then treated with rituximab. All patients responded within 2 months with the clinical activity score (CAS) improving from5.50.8 to 1.30.5. The eye disease remained quiescent in all with the positive results being sustained at 4-6 months after treatment.

Vision improved bilaterally in all 4 patients with dysthyroid optic neuropathy (DON). Proptosis remained stable (Hertel measurement, 243.7 mm before therapy and 23.63.7 mm after therapy; P = 0.17).

"These patients had already received the maximum level of steroid treatment," says Douglas. "Treatment with rituximab calmed inflammation, stopped progression of the disease, and saved the patients from having to undergo surgery."

Graves' disease (also known as thyroid eye disease) is an autoimmune condition in which white blood cells attack the thyroid gland which responds by secreting an excess amount of thyroid hormone. The hypermetabolic state is characterized by fast pulse/heartbeat, palpitations, profuse sweating, high blood pressure, irritability, fatigue, weight loss, heat intolerance, and loss of hair and alterations in hair quality.

Rituximab has been used to treat patients with other autoimmune diseases, including rheumatoid arthritis and in non-Hodgkin's B-cell lymphoma. The drug works by depleting B cells - the body's normal antibody-producing cells - that appear to go awry in autoimmune diseases.

"Treatment of the inflammatory component of Graves' eye disease has not advanced appreciably over several decades," says Douglas. High-dose steroids, sometimes in combination with orbital radiation, are still the first line treatment. But, says Douglas, "These are imperfect options because inflammation often recurs when the treatment ends." He is hopeful that rituximab can offer sustained improvement. Douglas observes that the results from a small case series must be viewed with some caution. But given the substantial benefits for patients treated with rituximab, he sees good reason to proceed with a large-scale clinical trial to test this promising new drug.

Source

Rituximab Treatment of Patients with Severe, Corticosteroid-Resistant Thyroid-Associated Ophthalmopathy; Ophthalmology, 2009; Chong et al.; DOI: 10.1016/j.ophtha.2009.05.029


University of Michigan Health System Newsroom



Archive issues: (50)

Archive list: 1 2 3 4 5 6 7 [8] 9 10 11 12 13 14 15 16 17

November 23, 2009 | Genetic Variant Slows AIDS Progression

Scientists report that a genetic variation appears to play a major role in slowing disease progression in HIV-infected patients.  In fact, those with the variation appear to take years longer to develop AIDS and die of complications of the disease.  "We're honing in on ...

November 22, 2009 | FDA To Reduce the Misuse of Medications

The FDA wants to reduce the misuse of medications, saying that at least 50,000 hospitalizations a year could be prevented if physicians, pharmacists, patients and parents would be more careful. And the cost of these preventable injuries is estimated at about $4 billion annually by the Institute of Medicine.  FDA commissioner Margaret A. Hamburg stated, "when I first started looking at this, I was stunned at the scope of the problem." She is right there is a huge problem in ...

November 21, 2009 | Diabetes Drug Byetta Linked to Kidney Problems

The FDA has received 78 reports of kidney problems related to Byetta, a drug by Amylin Pharmaceuticals and Eli-Lilly prescribed to treat type 2 diabetes. With the new findings, the drug's label will be updated to warn doctors and patients about this possible side effect.  Byetta (exenatide) was approved in 2005. It's known as an incretin mimetic, which copies the action of incretin GLP-1, a hormone that is released in response to eating food which causes insulin to be ...

Archive list: 1 2 3 4 5 6 7 [8] 9 10 11 12 13 14 15 16 17

Related articles:

Medical diagnosis

  There are no formal tests to diagnose erectile dysfunction. Some blood tests are generally done to exclude underlying disease, such as diabetes, hypogonadism and prolactinoma. Impotence is also related to generally poor physical health, poor dietary habits, obesity, and most specifically cardiovascular disease such as coronary artery disease and peripheral vascular ...

Section: Erectile Dysfunction

Acute prostatitis - diagnosis

  Acute prostatitis is relatively easy to diagnose due to its symptoms that suggest infection. The organism may be found in blood or urine, and some times in both. Common bacteria are Escherichia coli, Klebsiella, Proteus, Pseudomonas, Enterobacter, Enterococcus, Serratia, and Staphylococcus aureus. This can be a medical emergency in some patients and hospitalization with intravenous ...

Section: Prostatitis

History

  The earliest attempts at treating erectile dysfunction date back to Muslim physicians and pharmacists in the medieval Islamic world. They were the first to prescribe medication for the treatment of this problem, and they developed several methods of therapy for this issue, including a single-drug therapy method where a drug was prescribed and a "combination method of either a drug or food." Most of these drugs were oral medication, though a few patients ...

Section: Erectile Dysfunction

News

December 20, 2009

Wii, Xbox 360 and Other Video Games Offer Some Benefits

Wii, Xbox 360, PlayStation, and other video games are hot on holiday gift lists, but some parents wonder whether these games offer any benefits or are detrimental to kids. The results of a new study may put some minds at ease, while others ...

December 18, 2009

Should You Be Shoveling Snow?

Yes, the weather outside is frightful, and soon you will have to think about shoveling snow. But should you be the one doing the work? Who should and should not shovel snow, and how can you do it ...

December 17, 2009

Athletes who take NSAID's to prevent pain may be doing more harm than good

According to Stuart Warden, a researcher who studies musculoskeletal health and sports medicine, athletes who ritualistically take NSAID's to prevent post event and workout soreness and inflammation may be depriving the ...

Blogroll